Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$122.71 - $146.91 $3.05 Million - $3.66 Million
-24,886 Reduced 72.56%
9,410 $1.34 Million
Q1 2024

May 13, 2024

SELL
$102.11 - $135.92 $3.3 Million - $4.39 Million
-32,295 Reduced 48.5%
34,296 $4.4 Million
Q4 2023

Feb 13, 2024

BUY
$87.78 - $105.45 $5.85 Million - $7.02 Million
66,591 New
66,591 $6.89 Million
Q2 2023

Aug 14, 2023

BUY
$155.98 - $172.65 $2.31 Million - $2.56 Million
14,806 New
14,806 $2.4 Million
Q4 2022

Feb 13, 2023

BUY
$102.55 - $135.33 $267,758 - $353,346
2,611 Added 17.05%
17,924 $2.43 Million
Q3 2022

Nov 10, 2022

BUY
$95.28 - $116.93 $895,632 - $1.1 Million
9,400 Added 158.97%
15,313 $1.53 Million
Q2 2022

Aug 04, 2022

BUY
$103.24 - $121.81 $272,140 - $321,091
2,636 Added 80.44%
5,913 $659,000
Q1 2022

May 11, 2022

BUY
$93.1 - $112.54 $305,088 - $368,793
3,277 New
3,277 $364,000
Q4 2021

Feb 14, 2022

SELL
$95.88 - $117.08 $323,978 - $395,613
-3,379 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$84.42 - $106.62 $285,255 - $360,268
3,379 New
3,379 $324,000
Q2 2021

Aug 13, 2021

SELL
$67.66 - $84.76 $3.11 Million - $3.89 Million
-45,900 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$63.89 - $73.8 $1.28 Million - $1.48 Million
20,000 Added 77.22%
45,900 $3.21 Million
Q3 2020

Nov 16, 2020

BUY
$63.69 - $70.22 $656,007 - $723,266
10,300 Added 66.03%
25,900 $1.8 Million
Q2 2020

Aug 06, 2020

BUY
$58.54 - $67.94 $913,224 - $1.06 Million
15,600 New
15,600 $1.02 Million
Q3 2018

Oct 18, 2018

SELL
$46.76 - $51.24 $1.56 Million - $1.71 Million
-33,350 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$44.29 - $50.42 $1.48 Million - $1.68 Million
33,350 New
33,350 $1.54 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $237B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.